Learn about upcoming meetings relevant to HIV malignancies and recent news about NCI HIV/AIDS and HIV malignancy research.
Researchers from NCI and the Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab.
Researchers from the AIDS Malignancy Consortium have completed a cervical cancer trial in sub-Saharan Africa showing that women living with HIV can be treated with concomitant chemoradiotherapy using the same dose as HIV-negative women.
A NCI and NIAID supported clinical trial for Kaposi sarcoma (KS) suggests that paclitaxel is a superior treatment when compared to bleomycin and vincristine with ART or oral etoposide with ART for patients with advanced KS in low resource settings.
Investigators at the Center for Cancer Research, NCI describe how different simian immunodeficiency virus (SIV) vaccines respond differently to outside stimuli. The activation of hypoxia and the inflammasome in CD14+ monocytes result in a decrease risk of SIV acquisition.
Investigators at NCI identify the receptor for one of the HLA proteins (HLA-E) as a potential new target for HIV treatment. Blockade of this pathway has been implicated in many cancers and autoimmune diseases.
People living with HIV have an increased cancer burden, even in the absence of over immunosuprresion. In this review, NCI researchers Drs. Yarchoan and Uldrick describe the current epidemiology, pathogenesis and prevention strategies of HIV-associated cancers and related diseases.
NCI supported researchers have determined the structure of the Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8. This may provide a target for the developement of antiviral agents.